Welcome to MetrioPharm AG

MetrioPharm AG is a pharmaceutical development company focusing on therapies for chronic inflammatory diseases. We are developing a new class of self-regulating drugs against cellular oxidative stress.

Oxidative stress is one of the central causes of chronic inflammation, triggering a variety of diseases such as arthritis, dementia, cardiovascular disease and other degenerative age-related indications. MetrioPharm AGs development strategy is aimed specifically at these age-related inflammatory conditions (inflamm-aging).

Our lead compound MP1032 is in Phase II clinical development and has demonstrated therapeutic efficacy and an exceptionally good safety profile.

The aim of our development is to provide patients with earlier treatment with fewer health risks and less side effects.

In 2020, MetrioPharm published data on the treatment of SARS-CoV-2. MetrioPharm’s lead compound MP1032 has shown specific antiviral and anti-inflammatory activity in preclinical studies. The company is preparing a clinical trial to treat COVID-19 patients with MP1032.

MetrioPharm AG is headquartered in Zurich and operates a research facility in Berlin.